35 results about "Hepatitis B virus e Antigen" patented technology

The invention relates to a diagnosing reagent for hepatitis B, disclosing detection grains for e antigens of the hepatitis B virus, which are of the luminous grains coated by anti-HBE antibodies. The invention also discloses preparation and application for the detection grains for e antigens of the hepatitis B virus; moreover, the invention further discloses an outside-body diagnosis reagent box for detecting e antigens of the hepatitis B in a blood serum sample of human beings as well as a method for utilizing the light excitation chemiluminescence principle to quantitatively and qualitatively detect e antigens of the hepatitis B virus. The reagent box of the invention can be jointly used to diagnose the individual acute or chronic hepatitis B together with other blood serums and clinic information, and screen the hepatitis B for women in the perinatal period so as to judge the risk of newborn babies contaminating the hepatitis B.

The invention relates to the technical field of medicament, providing a novel application of coumarin compound imperatorin in preparing a medicament for preventing and treating virus hepatitis and resisting immunological liver injury or chemical liver injury. Pharmacological tests prove that the imperatorin has stronger activity of inhibiting hepatitis B surface antigen (HbsAg) and hepatitis B virus e antigen (HbeAg) and resisting the immunological liver injury or the chemical liver injury, so the imperatorin can be used for preparing the medicament for preventing and treating the virus hepatitis and resisting the immunological liver injury or the chemical liver injury. The imperatorin has the advantages of convenient preparation, wide sources, low price and high safety. The invention provides the novel application of the imperatorin, and provides a new medicinal source for preventing and treating the virus hepatitis and resisting the immunological liver injury or the chemical liver injury.

The invention discloses a pure natural functional drink suitable for a patient with chronic hepatitis B and a preparation method thereof. The pure natural functional drink is prepared from the following components in parts by weight: 0.5 to 2 parts of green tea extract, 0.1 to 0.5 part of grape skin extract, 0.1 to 0.5 part of Chinese yam extract, 0.05 to 0.2 part of Asian ginseng extract, 0.05 to 0.2 part of wild chrysanthemum flower extract, 0.05 to 0.2 part of ginkgo leaf extract, 0.5 to 2 parts of natural flavouring agent, 0.5 to 2 parts of natural sweetening agent, and the balance of water. The invention also discloses the preparation method of the pure nature functional drink for patient with chronic hepatitis B. Tests prove that if the patient with chronic hepatitis B drinks the pure natural functional drink for a long time, the effect of shifting hepatitis B virus e antigen to Yin can be achieved, which can help the patient with chronic hepatitis B to recover his/her health.

The invention provides a hepatitis B virus e antigen immune evasion detection gene chip and a kit, belonging to the gene chip technique field of clinical detection, and comprising: a gene chip of a specific DNA probe which detects hepatitis B virus e antigen immune evasion and is fixed on a solid phase carrier as well as a matched reagent; the matched reagent includes a treating fluid for treating serum samples, an amplifying solution for amplifying and labeling the treated samples, a hybridization solution in hybridization reaction with a micro-array, a cleaning solution, an enzyme-labeled working solution and a detection liquid; and the matched reagent and the hepatitis B virus e antigen immune evasion detection gene chip are used jointly in the detection process of the serum samples. The chip and the kit can detect the hepatitis B virus e antigen immune evasion, and avoid the clinical hepatitis B virus e antigen leak detection, thereby being favorable for judging the infectivity and conditions after curing of hepatitis B patients.

The invention provides a traditional Chinese medicinal preparation for conditioning and treating chronic hepatitis B, and belongs to the fields of traditional Chinese medicines and health care. The following raw materials are combined: peach kernel, fingered citron, fructus aurantii, endothelium corneum gigeriae galli, coix seeds, cordate houttuynia, dandelion, honeysuckle, herba portulacae, cape jasmine fruit, dark plum, liquorice root and jujube, so that by virtue of the synthetic effect of the various medicines, the preparation has the functions of promoting blood circulation and removing stasis, tonifying spleen and removing damp, strengthening healthy qi and nourishing liver, and clearing away heat and toxic materials, and therefore, an effect of conditioning and treating the chronic hepatitis B is achieved. Clinical detection data show that the traditional Chinese medicinal preparation has clear advantages on aspects of improving signs and symptoms, improving liver funcotion, hepatitis B virus e antigen (HBeAg) negative conversion ratio, HBeAg/anti-HBe serum conversion ratio and hepatitis B virus desoxyribonucleic acid (HBV-DNA) negative conversion ratio.

The invention relates to a nanometer magnetic particle chemiluminescence detection kit for a hepatitis B virus e antigen as well as a preparation method thereof and a detecting method thereof. The kit comprises a solution, which contains a fluorescein labeled hepatitis B virus e antigen antibody, a suspension, which is coated with magnetic particles of a fluorescein antibody, and a solution, which contains an alkaline phosphatase labeled hepatitis B virus e antigen antibody. According to the invention, the hepatitis B virus e antigen can be quantitatively detected with lower cost, higher accuracy and higher precision.

The present invention discloses a hepatitis B virus e antigen detection kit, which comprises a hepatitis B e antigen calibration substance, an anti-HBe monoclonal antibody coated plate, europium labeled anti-HBe monoclonal antibody, an assay buffer liquid, a fluorescence enhanced liquid and a concentrated washing liquid. The present invention further discloses a preparation method of the kit, and a method for detecting hepatitis B virus e antigen by using the kit. According to the present invention, the kit has advantages of high detection sensitivity, good specificity, simple operation, no pollution, and low cost, can be used for quantitative detection of the HBeAg content in human serum/plasma, and provides precise reference for the clinical hepatitis B individualized management treatment program.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of hepatitis B virus. Specifically, the invention relates to a monoclonal antibody of the hepatitis B virus e antigen, and also relates to a detection reagent (especially a chemiluminescence method) of the hepatitis B virus e antigen.

The invention relates to extract activity of Mallotus apelta and uses in prepartion of medicine for treating related diseases caused by hepatitis B. The extract of Mallotus apelta provided by the invention has basic components of apiolin, apiin-7-O-belta-D-glucoside, and flavonoids compounds of 5,7-dihydroxy-6-isopentene group-4'-methoxyl flavonone, flavonoids compounds Mallotus apelta have obvious inhibiting effect on hepatitis B virus surface antigen and hepatitis B virus e antigen ono surface of HepG 2215, and cabaple of inhibiting duplication of Duck Hepatitis B Virus deoxyribonucleic acid, withdraw rebound is weaker than positive reference medicine lamivudine, and hepatitis B is provided with a subsequent inhibiting effect after withdraw. The medicine according to the invention has strong function for fighting hepatitis B virus, clear active ingredient, which is suitable for industrial production, predictablly used for preparing medicine of preparing diseases infected by hepatitis B virus.

The invention discloses a hepatitis B virus e antigen (HBeAg) detection kit and a preparation method thereof. The hepatitis B virus e antigen (HBeAg) detection kit is composed of the following components: HBeAg antibody-coating magnetic microspheres, an HBeAg calibrator, an HBeAg antibody marker bound to lanthanides, an analytical buffer, a cleaning solution, an enhancement solution and an RFID card. Based on combination of the magnetic microspheres and a time-resolved immunoassay method, the drawbacks of long physical adsorption reaction time and slow detection result of an enzyme label plateare overcome, and the reaction time is greatly shortened; and besides, the advantages of high accuracy, high sensitivity, strong specificity, wide linear range, and stable and convenient detection ofa time-resolved detection technology can also be realized. The magnetic microspheres are coated with corresponding antigens or antibodies, due to the stereoscopic characteristic of the magnetic microspheres, the contact surface area of an immune response is greatly increased, the detection time is greatly shortened, and further optimization is made for the traditional two-step method detection, HBeAg detection only requires a one-step method, and a result can be obtained within 30 minutes.

The invention relates to application of benzyl-containing flavonoid lignan in preparation of a medicament for treating hepatitis B, in particular to application of flavonoid lignan and pharmaceutically-acceptable salt thereof in preparation of the medicament for eliminating hepatitis B e antigen, inhibiting hepatitis B virus desoxyribonucleic acid (HBV DNA) replication and treating viral hepatitis B. The flavonoid lignan can inhibit the activity of hepatitis B virus e antigen (HBeAg); the inhibition intensity of the flavonoid lignan under low concentration of 20 micrograms per milliliter is much higher than that of a positive control front-line medicament lamivudine and an interferon; and the compound with the concentration of 20 micrograms per milliliter displays an inhabitation ratio over 50 percent on the HBV DNA, so that the application of the flavonoid lignan in preparation of the medicament for eliminating the hepatitis B e antigen and the medicament for inhibiting the HBV DNA replication and treating hepatitis B viral diseases can be anticipated.

The invention discloses a preparation method of a red fluorescent antibody resisting HBeAg (hepatitis B virus e antigen). Genes of an mPylRS (pyrrolysyl-tRNA synthetase) of a synthesized methanosarcina mazei species and a plasmid pBK are recombined, and mPylRS-pBK is obtained; a mutant library lib-mPyl1RS-pBK is established with mPylRS-pBK as a template; lib-mPylRS-pBK is subjected to electroporation and then screened; NBDKRS-pBK plasmids are screened and recombined; DNA (deoxyribonucleic acid) resisting the HBeAg antibody is recombined with pBAD, and anti-HBeAg-4tag-pBAD is obtained; the plasmidsanti-HBeAg-4tag-pBAD and NBDKRS-pBK are transformed in a competent state, and a biological expression system for preparing the red fluorescent antibody resisting HBeAg is obtained. With the adoption of the preparation method, the red fluorescent antibody resisting HBeAg can be prepared, and the detection sensitivity is improved.

The invention discloses application of rotundic acid in preparation of an anti-hepatitis B virus (HBV) medicine for the first time, and especially discloses application of the rotundic acid in preparation of medicines for inhibiting secretion of HBV surface antigen or HBV E antigen. In-vitro HepG22.2.15 cell pharmacological experiments prove that rotundic acid has excellent anti-HBV effect, and has the advantages of relatively low effective concentration and relatively small cytotoxicity. The rotundic acid has an effect for inhibiting HBsAg and HBeAg, has the inhibition rates for HBsAg and HBeAg respectively being 39/5 percent and 40.2 percent at 100mu g/ml, and has the inhibition effect for HBV superior to that of positive control lamivudine, oleanolic acid and ovate leaf holly bark medicinal material extract.

The invention relates to application of human adipose derived mesenchymal progenitor cells in preventing or treating hepatitis B. Specifically, the human adipose derived mesenchymal progenitor cells can be used for preparing a pharmaceutical composition for treating the hepatitis B. The pharmaceutical composition, when applied to an object in need, can improve such indexes as hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B virus e antigen, hepatitis B virus e antibody, hepatitis B core antibody and the like, and can significantly reduce hepatitis virus DNA and lower ALT, so that the repair of hepatic function is promoted.

The invention discloses a preparation method of an anti-HBeAg (hepatitis B virus e antigen) green fluorescent antibody. DNA (deoxyribonucleic acid) of (PylRS) for M.Barkeri synthesis is recombined with plasmids pBK through genetic engineering means, and PylRS-pBK is obtained; the PylRS-pBK is taken as a template for establishment of a mutation database lib-PylRS-pBK; the lib-PylRS-pBK is subjected to electroporation and screening; CoukRS-pBK plasmids are screened and recombined; DNA of an anti-HBeAg antibody is recombined with pBAD, and anti-HBeAg-4tag-pBAD is obtained; plasmids anti-HBeAg-4tag-pBAD and CoukRS-pBK are converted into a competent state, and a biological expression system for preparing the anti-HBeAg green fluorescent antibody is obtained. The preparation of the anti-HBeAg green fluorescent antibody is realized, and the detection sensitivity is improved.

Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.

A novel application of pedunculoside in preparation of anti-(hepatitis-B-virus) medicines is disclosed for the first time by the invention. The application includes an application of the pedunculoside in preparation of medicines inhibiting hepatitis B surface antigen secretion or hepatitis B virus E antigen secretion. In-vitro HepG22.2.15 cell pharmacological experiments prove that: the pedunculoside has good anti-HBV functions and has characteristics of a low effective concentration and low cell toxicity; the pedunculoside can inhibit HBsAg and HBeAg; when the concentration is 100 [mu]g/mL, the HBsAg inhibiting rate and the HBeAg inhibiting rate are 34.8% and 35.2% respectively; and an HBV inhibiting function of the pedunculoside is higher than HBV inhibiting functions of positive controls which are lamivudine, oleanolic acid and a ilex rotunda bark extract product.